Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis

Journal of Magnetic Resonance Imaging

Volumn 25, Issue 5, 2007, Pages 881-883

  Pedersen, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM EDETATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISSOCIATION CONSTANT; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; EDITORIAL; FIBROSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; THERMOSTABILITY; UNSPECIFIED SIDE EFFECT;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY; MAGNETIC RESONANCE IMAGING; SAFETY; SKIN DISEASES;

EID: 34247889994     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20983     Document Type: Editorial

References (25)

1. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
2. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
3. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-2621.
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-592.
5. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis. an emerging threat among renal patients. Semin Dial 2006;19:191-194.
6. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238-249.
7. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1001.
8. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358.
9. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin induced wound-healing response. Am J Pathol 2003;163:993-1000.
10. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006;145:234-235.
11. Molteni A, Ward WF, Ts'ao CH, et al. Cytostatic properties of some angiotensin 1 converting enzyme inhibitors and of angiotensin 11 type 1 receptor antagonists. Curr Pharm Des 2003;9:751-761.
12. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy. Are ACE inhibitors the missing link? Arch Dermatol 2004;140:1401.
13. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205-213.
14. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
15. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
16. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
17. White GW, Gibby WA, Tweedle MF. Comparison of Gadolinium (DTPA-BMA) (Omniscan) versus Gadolinium (HP-DO3A) (Pro-Hance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
18. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-448.
19. Normann PT, Hustvedt SO, Storflor H, Hals PA. Preclinical safety and pharmacokinetic profile of gadodiamide injection. Clin MRI 1995;5:95-101.
20. Keen CL, Graham TW. Trace elements. In: Kaneko JJ, editor. Clinical biochemistry of domestic animals, 4th edition. San Diego: Academic Press Inc; 1989. p 753-795.
21. Chang CA. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. Invest Radiol 1993;28(Suppl 1):S21-S27.
22. Sauer JM, Waalkes MP, Hooser SB, Kuester RK, McQueen CA, Sipes IG. Suppression of Kupffer cell function prevents cadmium induced hepatocellular necrosis in the male Sprague-Dawley rat. Toxicology 1997;121:155-164.
23. Normann PT, Joffe P, Martinsen I, Thomsen HS. Quantification of gadodiamide as Gd in serum, peritoneal dialysate and faeces by inductively coupled plasma atomic emission spectroscopy and comparative analysis by high-performance liquid chromatography. J Pharm Biomed Anal 2000;22:939-947.
24. Arsenault TM, King BF, Marsh JW Jr, et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996;71:1150-1154.
25. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991;22:222-228.